SRPT vs. RDY, KRTX, CTLT, LEGN, VTRS, ROIV, BGNE, ASND, TEVA, and CYTK
Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Dr. Reddy's Laboratories (RDY), Karuna Therapeutics (KRTX), Catalent (CTLT), Legend Biotech (LEGN), Viatris (VTRS), Roivant Sciences (ROIV), BeiGene (BGNE), Ascendis Pharma A/S (ASND), Teva Pharmaceutical Industries (TEVA), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical preparations" industry.
Sarepta Therapeutics (NASDAQ:SRPT) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.
Sarepta Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.
Dr. Reddy's Laboratories has a net margin of 19.26% compared to Sarepta Therapeutics' net margin of -43.11%. Dr. Reddy's Laboratories' return on equity of 20.97% beat Sarepta Therapeutics' return on equity.
Sarepta Therapeutics received 1109 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 75.40% of users gave Sarepta Therapeutics an outperform vote while only 58.95% of users gave Dr. Reddy's Laboratories an outperform vote.
86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 14.0% of Dr. Reddy's Laboratories shares are held by institutional investors. 7.4% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Sarepta Therapeutics presently has a consensus price target of $158.38, indicating a potential upside of 34.76%. Dr. Reddy's Laboratories has a consensus price target of $80.00, indicating a potential upside of 11.53%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than Dr. Reddy's Laboratories.
Dr. Reddy's Laboratories has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sarepta Therapeutics had 10 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 10 mentions for Sarepta Therapeutics and 0 mentions for Dr. Reddy's Laboratories. Sarepta Therapeutics' average media sentiment score of 0.97 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media.
Summary
Sarepta Therapeutics beats Dr. Reddy's Laboratories on 11 of the 18 factors compared between the two stocks.
Get Sarepta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sarepta Therapeutics Competitors List
Related Companies and Tools
